IMUTEX Ltd
Imutex is developing a universal flu vaccine that is ready for Phase IIa clinical trials, utilizing a novel antigen design to elicit broad immune responses. This vaccine aims to address the limitations of current seasonal flu vaccines, which often fail to provide adequate protection against emerging strains.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$20.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Imutex is developing a universal flu vaccine that is ready for Phase IIa clinical trials, utilizing a novel antigen design to elicit broad immune responses. This vaccine aims to address the limitations of current seasonal flu vaccines, which often fail to provide adequate protection against emerging strains.